Clinical trials: Dysthyroid Orbitopathy
Graves Ophthalmopathy
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
This study is a randomized, controlled, multi-center clinical study, the purpose is to evaluate the efficacy and safety of rapamycin combined with methylprednisolone in the treatment of moderate to severe active GO.
- Trial name
- NCT05532072
- Testing
- Rapamycin, Methylprednisolone
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Thyroid Associated Orbitopathy
Changes in Orbital Macrovascular and Intraocular Microvascular Blood Flow After Orbital Decompression Surgery in Patients With Thyroid Eye Disease
This study aims to evaluate the effects of balanced orbital decompression surgery in patients with inactive thyroid-associated orbitopathy.
- Trial name
- BOD-VASC (NCT07393230)
- Testing
- Balanced Orbital Decompression Surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled.
- Trial name
- NCT04583735
- Testing
- TEPEZZA
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Amgen
Ophthalmopathy, Thyroid-Associated
Rituximab (RTX) Therapy in Patients With Active TAO
Thyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients with Graves disease. Its combination of protrusion affecting the looks of the patient and pain is often severely affecting the quality of…
- Trial name
- NCT02378298
- Testing
- Rituximab, Iv Methylprednisolone, peroral methylprednisolone and Methotrexate
- Where
- 5 sites in Sweden
- Volunteers
- 38 people
- Sponsor
- Göteborg University
Thyroid Eye Disease, TED
Treatment of Chronic Thyroid Eye Disease With MHB018A
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
- Trial name
- NCT07622121
- Testing
- MHB018A injection
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves Disease, Graves Disease (Basedow's Disease)
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Graves' disease is an autoimmune condition that causes an overactive thyroid. Some people with Graves' disease develop thyroid eye disease, also called Graves' orbitopathy, which can cause swelling around the eyes, eye…
- Conditions
- Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy
- Trial name
- ATORGO (NCT07883356)
- Testing
- Atorvastatin
- Where
- 7 sites in Sweden
- Volunteers
- 554 people
- Sponsor
- Region Skane
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05524571
- Testing
- Batoclimab
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Eye Disease, Graves Orbitopathy
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- NCT06112340
- Testing
- linsitinib
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sling Therapeutics, Inc.
Thyroid Eye Disease
Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
The main objective of this study is to assess the number of participants with proptosis response as of last intravenous infusion of teprotumumab.
- Trial name
- NCT07085117
- Testing
- Teprotumumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Amgen
Thyroid Eye Disease, TED
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-1 (NCT05987423)
- Testing
- Satralizumab
- Where
- 46 sites in United States, Argentina and 8 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Thyroid Eye Disease
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.
- Trial name
- NCT07113262
- Testing
- IBI311
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid-Associated Ophthalmopathy
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with…
- Trial name
- NCT00288522
- Testing
- Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Ipsen
Thyroid Associated Ophthalmopathies
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152340
- Testing
- IBI311, Glucocorticoids
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Changzheng Hospital
Graves' Orbitopathy
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation.
- Trial name
- ABLAGO (NCT04776993)
- Testing
- Methimazole, Radioiodine or thyroidectomy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Thyroid Eye Disease, TED
Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the…
- Trial name
- NCT07056114
- Testing
- The patients with active or inactive TED
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Thyroid Associated Ophthalmopathies
Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues
Prostaglandin analogues eye drops are common and effective treatment for decreasing Intra-Ocular Pressure (IOP) in Glaucoma patients.
- Trial name
- NCT02155049
- Testing
- bimatoprost 0.03%
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Thyroid Eye Disease, Graves Orbitopathy
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- LIDS (NCT05276063)
- Testing
- Linsitinib
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 90 people
- Sponsor
- Sling Therapeutics, Inc.
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Graves Ophthalmopathy
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
The purpose of this study is to examine the effects of Azithromycin (a macrolide class antibiotic), given three times weekly, for patients with active moderate-severe, non sight-threatening, Graves Orbitopathy.
- Trial name
- NCT01379196
- Testing
- Azithromycin
- Sponsor
- Rabin Medical Center
Graves Ophthalmopathy
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease
Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments.
- Trial name
- TED (NCT03324022)
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital